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The uses of highly selective PPARβ/δ ligands and PPARβ/δ knockout mice have shown a direct ability of PPARβ/δ to regulate
angiogenesis in vitro and in vivo in animal models. PPARβ/δ ligands induce the proangiogenic growth factor VEGF in many cells
and tissues, though its actions in the eye are not known. However, virtually, all tissue components of the eye express PPARβ/δ.
Both angiogenesis and in particular VEGF are not only critical for the development of the retina, but they are also a central com-
ponent in many common pathologies of the eye, including diabetic retinopathy and age-related macular degeneration, the most
common causes of blindness in the Western world. This review, therefore, will discuss the recent evidence of PPARβ/δ-mediated
angiogenesis and VEGF release in the context of ocular disorders.
Copyright © 2008 David Bishop-Bailey. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
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1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPAR’s) belong
to the steroid receptor superfamily of ligand-activated tran-
scription factors [1]. Three PPAR’s, PPARα,P P A R β/δ,a n d
PPARγ, have been identiﬁed [2]. PPARα is predominantly
expressed in liver, heart, kidney, brown adipose tissue, and
stomachmucosa;PPARγ isfoundprimarilyinadiposetissue;
PPARβ/δ is the most ubiquitously expressed [3, 4], though
its roles in physiological and pathophysiological processes
are far from clear, particularly, in human tissue. The re-
cent development of PPARβ/δ knockout andtransgenicmice
has started to implicate roles for PPARβ/δ in adipose tissue
formation, metabolism, wound healing, brain development,
placental function, atherosclerosis, colorectal carcinogenesis,
andskeletalmusclefunction[5–7].Inthisreview,theemerg-
ing role of PPARβ/δ in regulating endothelial function and
angiogenesis will be discussed with a particular emphasis to
its relevance in the eye.
2. PPARβ/δ LIGANDS
A number of synthetic PPARβ/δ compounds have been
described including GW0742X, GW2433, GW9578, L-
783,483, GW501516, L-796,449, L-165,461, and compound
F[ 8, 9]. In addition, putative endogenous PPARβ/δ ac-
tivators include fatty acids [3, 10], triglycerides [11],
the cyclooxygenase (COX) product, prostacyclin [10],
the COX/prostacyclin synthase derived endocannabinoid
metabolites [12], and all-trans retinoic acid (ATRA) [13].
ATRA is derived from vitamin A (retinol) which is found at
itshighestlevelsintheeyeandisessentialforitsdevelopment
and function [14]. Retinol is converted to retinaldehyde, a
componentofrhodopsin[14]andafunctionalPPARγ antag-
onist [15, 16] ,w h i c hi nt u r ni sm e t a b o l i s e dt oA T R Ab yr e t i -
nal dehydrogenases [14]. ATRA has its own family of high-
aﬃnity nuclear receptors, the retinoic acid receptor (RAR)α,
-β,a n d- γ, which like the PPAR’s act as heterodimers with
RXRα,- β,a n d- γ, the receptors for the ATRA isomer 9-cis
retinoic acid [17]. Although ATRA can activate PPARβ/δ,
it is not known which, if any, of its actions are mediated
by PPARβ/δ. However, since ATRA is present in such large
quantities in ocular tissue, it is potentially an important site
for its actions.
3. PPARβ/δ AND ENDOTHELIAL CELLS
Endothelial cells play critical roles in vascular biology, being
boththeprotectiveinnerliningofvesselsandthelocalsitefor
delivery of oxygen to all tissues. Angiogenesis is the process2 PPAR Research
ofnewbloodvessel/capillaryformationfromexistingvessels,
and hypoxia is a major signal which drives the process [18].
PPARα,PP ARβ/δ,andPP ARγ areallexpressedinendothelial
cells [19]. PPARα and PPARγ have well-characterised roles
in endothelial cells, both being in general anti-inﬂammatory,
antiproliferative [1], and antiangiogenic in a variety of in
vitro and in vivo models, including tumorigenesis [20]a n d
laser-induced retinal injury [21]. In contrast, the role of
PPARβ/δ in this important cell type has only recent start-
ing to be elucidated. Initial reports using prostacyclin as a
ligand suggested that like PPARα and PPARγ,P P A R β/δ pro-
moted endothelial cell apoptosis [22]. In contrast, the use of
highlyselectivesyntheticligandshasrevealedacontradictory
role for PPARβ/δ regulating endothelial cell survival, prolif-
eration, and angiogenesis.
3.1. PPARβ/δ andendothelialcell
proliferationandsurvival
Long- [23] and short-term [24] culture of endothelial cells
with the selective ligand GW501516 induces endothelial cell
proliferation, an eﬀect associated with the induction of the
VEGF receptor (Flt-1; VEGF R1) and VEGF production [23,
24]. In addition to inducing proliferation, PPARβ/δ activa-
tionprotectscellsfromoxidant-induced apoptosis.Synthetic
PPARβ/δ ligandsoractivationoftheCOX-prostacyclinpath-
way, which signals through PPARβ/δ, induce the endothelial
expression of 14-3-3α protein [25]. 14-3-3 proteins are anti-
apoptotic and anti-inﬂammatory molecules [26]. PPARβ/δ-
induced 14-3-3α blocks oxidant- (H2O2-) induced apopto-
sis by sequestering the proapoptotic protein Bad, stopping
its translocation to mitochondrial membranes, where it ini-
tiates cytochrome c release and the subsequent activation of
the proapoptotic caspase cascade [25].
3.2. PPARβ/δ andangiogenesis
In addition to having eﬀects on endothelial cell prolifera-
tion, PPARβ/δ activation potently induces angiogenesis of
humanvascularendothelialcellsintumourextracellularma-
trix in vitro and in a murine matrigel plug model in vivo
[24]. In addition, the putative PPARβ/δ ligand prostacy-
clin analogues [27]a n dA T R A[ 28] also induce angiogene-
sis, though the latter appears mostly dependent on its RARα
receptor rather than PPARβ/δ [29]. In human endothelial
cells, a major trigger for morphogensis induced by PPARβ/δ
stimulation was the stimulated release of VEGF [24]. In ad-
dition to VEGF, mRNA for the matrix metalloproteinase
(MMP)-9, a protease important for cell migration was also
elevated by PPARβ/δ activation [24]; however, whether this
was secondary to VEGF release was not tested. VEGF is ex-
pressed as four main splice variants (by amino acid size:
VEGF121,V E G F 165,V E G F 189,V E G F 206)[ 29]. VEGF (VEGF-
A; VEGF165) is a well-characterised central mediator of en-
dothelial cell growth and angiogenesis [29, 30]. Two en-
dothelial VEGF tyrosine kinase receptors have been identi-
ﬁed:VEGFR-1/Flt-1,andVEGFR-2/KDR/Flk1.VEGFR2ap-
pears to be the most important receptor in VEGF-induced
mitogenesis and permeability [29, 30]. In addition, in two
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Figure 1: Proangiogenic/prosurvival pathways of PPARβ/δ in en-
dothelial cells. PPARβ/δ is expressed in endothelial cells. PPARβ/δ
activation induces (solid line) the expression of VEGF and its re-
ceptor Flt-1, matrix metalloproteinase (MMP)-9, thrombospondin
and its receptor CD36, the chloride intracellular channel protein
(CLIC)-4,thecell cycle inhibitorp57kip2,andtheantiapoptoticpro-
tein14-3-3α.Incontrast,thecellularretinolbindingprotein-1isde-
creased (dashed line) by PPARβ/δ activation. For those interested, a
complex transcriptional map of the potential role of PPARβ/δ as a
hub node in tumour angiogenesis has recently also been formed as
detailed in [32].
recent studies, the growth of PPARβ/δ wild-type tumours or
angiogenesis in matrigel plugs in PPARβ/δ knockout mice
was tested [31, 32]. The tumours in PPARβ/δ knockout mice
compared to wild-type mice were associated with a dimin-
ished blood ﬂow and an immature hyperplastic microvas-
cular structures. Moreover, the retroviral introduction of
PPARβ/δ into matrigel plugs was able to rescue the knockout
phenotype by triggering microvessel maturation [31]. In the
latter of these studies, PPARβ/δ was examined in tumours
from patients who had undergone “angiogenic switch” a
proangiogenic state involved in tumour progression [32].
PPARβ/δ correlatedwithadvancedpathologicaltumorstage,
increased risk for tumor recurrence, and distant metastasis,
andwas,therefore,suggestedasahubnodetranscriptionfac-
tor regulating tumour angiogenesis [32].
Genomic and proteomic analyses of the PPARβ/δ knock-
out endothelial cells isolated from matrigel plugs have also
led to the identiﬁcation of a number of additional candi-
date genes to mediate the actions of PPARβ/δ in angiogen-
esis. In particular, the Cdkn1c gene which encodes the cell
cycle inhibitor p57Kip2 is a direct PPARβ/δ target gene that
mediates PPARβ/δ eﬀects on cell morphogenesis [31]. In ad-
dition, CD36 and thrombospondin were also decreased in
matrigel-invading endothelial cells from PPARβ/δ knockout
mice [31]. Thrombospondins by directly interacting with
CD36 inhibit angiogenesis in vivo [33, 34]. Similarly, a pro-
teomic analysis by the same group [35]o nP P A R β/δ knock-
out endothelial cells has also revealed a decreased expres-
sion of the chloride intracellular channel protein (CLIC)-4
in migrating endothelial cells from PPARβ/δ knockout mice.
In contrast, the expression of cellular retinol binding pro-
tein CRBP1 is increased in migrating endothelial cells from
PPARβ/δ knockout mice [35]. CLIC-4 promotes and plays
an essential role during tubular morphogenesis [36], while
CRBP1 inhibits cell survival pathways by acting as an in-
hibitoroftheAKTsignallingpathway[37],anadditionalim-
portant signalling signal for angiogenesis to occur [38].David Bishop-Bailey 3
The combination of these studies show PPARβ/δ activa-
tion induces endothelial cell mitogen and diﬀerentiation sig-
nals, including VEGF, 14-3-3α, CD36 and thrombospondin,
CLIC4, CRBP-1, and p57KIP2,a l lo fw h i c hm a ya c ti nac o -
ordinate manner to bring about the functional morphogenic
changes associated with angiogenesis.
3.3. PPARβ/δ andVEGF
Although the direct evidence for a role of PPARβ/δ in an-
giogenesis is relatively new, there has been an increasing
literature regarding PPARβ/δ regulated tumour cell growth
via inducing tumour cells to release VEGF. PPARβ/δ lig-
andsinduceVEGFinbladdercancercells[39],humanbreast
(T47D, MCF7), and prostate (LNCaP, PNT1A) cancer cell
lines, along with its receptor ﬂt-1 [22], but not (HT29,
colon; HCT116, colon; LS-174T, colon; HepG2, hepatoma;
and HuH7, hepatoma) cell lines [40].
In a genetic model of intestinal polyp development
APC/min mouse, deletion of PPARβ/δ decreases intestinal
adenoma growth and inhibits tumour-promoting eﬀects of
the PPARβ/δ agonist GW501516 [41]. Moreover, activation
ofPPARβ/δ upregulatedVEGFincoloncarcinomacells,pro-
moting colon tumour epithelial cell survival through activa-
tion of AKT signalling [41]. Angiogenesis was not studied
in this model, however, any substantial tumour growth re-
quires a blood supply and angiogenesis to allow it to develop.
In contrast, in human colon and liver cancer cell lines [40],
PPARβ/δ ligands had no eﬀect on human cancer cell growth,
AKT, VEGF or COX-2 expression in vitro or on these makers
in the liver, colon, and colon polyps in mice treated in vivo
[40]. The roles of PPARβ/δ in VEGF- mediated tumorigene-
sis are, therefore, still in need of further clariﬁcation.
3.4. ExpressionofPPARβ/δ intheeye
Angiogenesis regulates both the physiological development
and many of the most common pathophysiology’s of the eye.
As yet, there is no direct evidence linking PPARβ/δ and an-
giogenesis in the eye, however, PPARβ/δ is clearly expressed
at least in murine ocular tissue. PPARβ/δ is expressed in the
eye ciliary body epithelial cells, cornea epithelial cells, cornea
endothelium, cornea ﬁbroblast, retina inner nuclear layer,
and retina ganglion cell layer [42]. Although one must be
cautious interpreting data from nonocular tissue to the eye
[43], as discussed previously and following, pathways that
have direct relevance to ocular angiogenesis are clearly reg-
ulated by PPARβ/δ and are therefore worthy of discussion.
4. VEGF AND OCULAR ANGIOGENESIS
VEGF is essential in retinal vasculature development [44].
Initially blood vessels grow from the optic nerve outwards.
Astheretinaltissuedevelopsviaacomplexinterplaybetween
diﬀerentcellularcomponentssuchasneurons,glia,endothe-
lial cells, pericytes, and immune cells, the increased oxygen
demand induces hypoxia, the main stimulant for new vessel
growth via angiogenesis. As the tissue/vasculature develops
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Figure2:Antiinﬂammatory/anticoagulationpathwaysofPPARβ/δ.
PPARβ/δ activation in endothelial cells reduces NFκB activation
and the induction of vascular cell adhesion molecule (VCAM)-1,
and monocyte chemoattractant protein (MCP)-1, along with the
release of tissue factor. PPARβ/δ is expressed in platelets and mono-
cytes/macrophages. PPARβ/δ ligands reduce platelet aggregation
via a rapid nongenomic mechanism. In macrophages, PPARβ/δ lig-
andsreleasethetranscriptionalcorepressorBCL-6fromitscomplex
with PPARβ/δ. Free BCL-6 suppresses the release of MCP-1, MCP-
3, and IL-1β.
and gets oxygenated, hypoxia and VEGF decrease limiting
new vessel growth [44].
In contrast, neovascularisation of the adult eye via an-
giogenesis is a critical component of many disorders of the
eye including retinopathy of prematurity, diabetic retinopa-
thy, and age-related macular degeneration, the latter two be-
ing the leading causes of blindness in the Western world (as
reviewed in detail elsewhere [29, 45–48]). Pathological neo-
vascularisation resulting from tissue damage and hypoxia re-
sults in a more complex “inﬂammatory” angiogenesis. These
new vessels are often fragile and leaky leading to haemor-
rhage and vision disturbance and loss. The main trigger for
this new vessel growth still appears to be hypoxia induced
VEGF expression [29, 45–48]. Angiogenesis is a homeostatic
repair mechanism that is required for the reoxygenation of
the damaged ischemic tissue [29, 45–48]. The problems that
arise with pathologies such as age-related macular degenera-
tion and diabetic retinopathy are that this new vessel growth
is leaky and has a critical inﬂammatory component. VEGF
(inparticularVEGFA;VEGF165)inadditiontodirectlystim-
ulating angiogenesis is also a potent vascular permeability
factor and appears to play a role in regulating the local in-
ﬂammation associated with pathological neovascularisation
[49]. VEGF has become a clear therapeutic target for the
treatment of angiogenesis in the eye. The clinical importance
of VEGF as a target has recently been further demonstrated
with the development and use of two new drugs targeting
its actions: Macugen (pegaptanib), an aptamer, and Lucentis
(ranibizumab), a FAB fragment, from a humanised mono-
clonal antibody, which both functionally block VEGF. More-
over,MacugenandLucentisbothshowclinicaleﬃcacyinpa-
tients with age-related macular degeneration [50]; especially
when treated early and a mature neovasculature has yet to
form. These therapies require local delivery by intravitriol4 PPAR Research
injection, which although having the beneﬁt of overcoming
problems such as systemic VEGF blockade, they are clearly
still not ideal, and show that new therapies are still required.
5. PPARβ/δ OCULAR ANGIOGENESIS,
INFLAMMATION, AND COAGULATION
Angiogenesis associated with pathophysiology is often asso-
ciated with multiple process such as tissue damage, inﬂam-
mation, and coagulation. In contrast, developmental angio-
genesismaybeasimplerhypoxiadrivenevent.Indeed,anin-
ﬂammatory response is induced by VEGF during pathologi-
cal but not physiological ischemia-induced retinal angiogen-
esis [51, 52]. Moreover, speciﬁcally blocking inﬂammatory
cytokines monocyte chemotactic protein-1 and macrophage
inﬂammatory protein-1a can reduce retinal neovascularisa-
tion [53]. Tissue factor is a critical initiator of blood coag-
ulation, and is associated with tumour aggressiveness and
angiogenesis in a variety of cancer cells [54], as well as in
choroidal neovascularisation where it promotes ﬁbrin for-
mation and the growth of the choroidal angiogenic com-
plex [55]. One important facet of pathological angiogene-
sis may therefore be this involvement additional pathways,
and a complex interplay between processes of tissue damage,
hypoxia, inﬂammation, and coagulation. A long-term thera-
peutic aim may therefore be to have revascularisation of hy-
poxic tissue similar to development without these additional
inﬂammatory/coagulation processes.
PPARβ/δ induces VEGF in a number of cell types and
induces angiogenesis. Therefore, one may predict that a
PPARβ/δ antagonistwouldbeusefultotreatoratleasttestin
models of eye disease that involve neovascularisation. How-
ever, PPARβ/δ seems consistent with other PPAR’s in that it
also has anti-inﬂammatory and anticoagulation properties,
suggesting that its properties in ocular angiogenesis may be
more complex than one would originally predict.
PPARβ/δ activation suppresses endothelial cell tissue fac-
tor expression [12]. PPARβ/δ is also expressed in platelets
where its ligands reduce platelet aggregation to a variety of
stimuli [56] .S i m i l a rt oP P A R α and PPARγ,P P A R β/δ ligands
are anti-inﬂammatory in endothelial cells, inhibiting TNFα-
induced upregulation of expression of vascular cell adhe-
sion molecule-1, monocyte chemoattractanct protein-1, and
nuclear factor (NF)κB translocation [57]. In macrophages,
PPARβ/δ controls inﬂammatory status by its association and
disassociation with the transcriptional repressor BCL-6 [58];
in the absence of ligand, PPARβ/δ physically associates with
andinhibitsthisanti-inﬂammatoryBCL-6.WhenaPPARβ/δ
ligand is added, BCL-6 dissociates from PPARβ/δ and re-
presses the inﬂammation and levels of monocyte chemoat-
tractanct protein-1, -3, and IL-1β [58].
6. CONCLUSION
PPARβ/δ induces angiogenesis and protects endothelial cells
from oxidant damage. A common signal for PPARβ/δ acti-
vation in endothelial cells or surrounding tissue may be the
induction of VEGF. PPARβ/δ is expressed in all tissues in the
eye, however its function has yet to be tested in physiologi-
cal processes, development, or pathophysiological disorders.
The development of both the eye and common pathologi-
cal disorders requires angiogenesis, with VEGF being a pri-
mary signalling molecule. Blocking PPARβ/δ may therefore
provide a new therapy to treat angiogenic eye disorders. The
diﬀerence between “physiological” and “pathophysiological”
angiogenesismaybeadditionalcomponentsofinﬂammation
and coagulation. PPARβ/δ ligands reduce inﬂammation and
components of the coagulation cascade. It will be of great
interest to test the roles of PPARβ/δ in the eye as a poten-
tial proangiogenic stimulus reliving the hypoxia, while po-
tentially still capable of reducing the damaging inﬂamma-
tory/coagulation signals.
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